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Summary
Toll-like receptor 10 (TLR10) is the only member of the human Toll-like
receptor family with an inhibitory function on the induction of innate
immune responses and inflammation. However, its role in the modulation
of trained immunity (innate immune memory) is unknown. In the pre-
sent study, we assessed whether TLR10 modulates the induction of
trained immunity induced by b-glucan or bacillus Calmette–Guerin
(BCG). Interleukin 10 receptor antagonist production was increased upon
activation of TLR10 ex vivo after BCG vaccination, and TLR10 protein
expression on monocytes was increased after BCG vaccination, whereas
anti-TLR10 antibodies did not significantly modulate b-glucan or BCG-in-
duced trained immunity in vitro. A known immunomodulatory TLR10
missense single-nucleotide polymorphism (rs11096957) influenced trained
immunity responses by b-glucan or BCG in vitro. However, the in vivo
induction of trained immunity by BCG vaccination was not influenced by
TLR10 polymorphisms. In conclusion, TLR10 has a limited, non-essential
impact on the induction of trained immunity in humans.
Keywords: innate immunity; Toll-like receptor 10; trained immunity.
Abbreviations: BCG, bacillus Calmette–Guerin; BSA, bovine serum albumin; IFN-c, interferon-c; IL, interleukin; IL-1Ra, IL-1
receptor antagonist; LPS, , lipopolysaccharide; mAb, monoclonal antibody; QTL, quantitative trait loci; SNP, single-nucleotide
polymorphism; TLR, Toll-like receptor; TNF-a, tumor necrosis factor-a
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Introduction
Toll-like receptors (TLRs) are pattern recognition receptors
that are essential to provide a first line of defense upon inva-
sion of pathogens. TLRs activate intracellular signaling path-
ways upon recognition of pathogen-associated molecular
patterns, which results in activation of the innate immune
response. Ten human TLRs have been described, and
although the function of most TLRs has been studied exten-
sively, there is relatively limited knowledge on the biological
role of TLR10 during the human immune response.1,2
Human TLR10 was discovered in 2001,3 and is located
on chromosome 4 within the TLR2 gene cluster, together
with TLR1 and TLR6. TLR10 is structurally similar to the
other TLR family members and is phylogenetically most
related to TLR1 and TLR6.3 TLR10 mRNA is highly
expressed in lymphoid tissues,3 and is expressed in differ-
ent immune cells, including B cells, dendritic cells,4–6 and
monocytes.4,7 Currently, there is no natural ligand identi-
fied for TLR10. TLR10 is able to homodimerize, as well
as heterodimerize with TLR1 and TLR2.6,7 Surprisingly,
TLR10 does not induce the classical TLR downstream sig-
naling pathway, even though it has been shown that it
can associate with myeloid differentiation primary
response 886 and protein kinase B.7
Although it was initially reported that TLR10 had a
pro-inflammatory function,8,9 the majority of reports
have demonstrated anti-inflammatory properties of
TLR10.4,7,10,11 TLR10 single nucleotide polymorphisms
(SNPs) strongly influence pro-inflammatory cytokine
production in humans, and in hTLR10 transgenic mice,
significantly lower interleukin-6 (IL-6) and KC (mouse
analog of human IL-8) concentrations in plasma were
found compared with wild-type mice.7 TLR10 has been
shown to be involved in the induction of innate immune
responses to influenza and is involved in Helicobacter
pylori infection.9,12,13 Moreover, polymorphisms in TLR10
have been associated with various diseases, including
complicated skin and skin-structure infections,14 tubercu-
losis,15 prostate cancer16 and Crohn’s disease.17,18
It is well documented that IL-1b is one of the crucial
cytokines involved in innate immune memory and in the
induction of trained immunity.19 Trained immunity is a
process in which human innate immune cells such as
monocytes can undergo extensive metabolic and epigenetic
reprogramming upon certain infections or vaccinations,
resulting not only in long-term enhanced immune
responses and resistance to heterologous infections,20 but
also in induction of maladaptive immune responses in
inflammatory diseases when cells are stimulated by endoge-
nous ligands.21 Due to the important modulatory role of
TLR10 on innate immune responses, including the produc-
tion of the anti-inflammatory cytokine IL-1 receptor antag-
onist (IL-1Ra),7 we hypothesized that TLR10 may also
regulate the induction of trained immunity.
Materials and methods
Reagents
RPMI-1640 (Dutch modified; Gibco, Life Technologies,
Waltham, MA) was used as culture medium supple-
mented with 5 lg/ml gentamicin (Centrafarm B.V.,
Etten-Leur, the Netherlands), 2 mM L-glutamine (Gibco),
and 1 mM pyruvate (Gibco). Mouse anti-TLR10 mono-
clonal antibody (mAb) 3C10C5 (Sanbio, Tokyo, Japan)
was used, and mouse IgG1 isotype control (R&D Systems,
Minneapolis, MN) as control. Synthetic Pam3SK4
(Pam3Cys) was purchased from EMC Microcollections
(T€ubingen, Germany) and Borrelia burgdorferi, ATCC
strain 35210, was cultured at 33° in Barbour–Stoenner–
Kelley-H medium (Sigma, St Louis, MO) supplemented
with 6% rabbit serum. Spirochetes were grown to late-
logarithmic phase and motility was tested by dark-field
microscopy. Spirochetes were counted using a Petroff–
Hauser counting chamber. Upon centrifugation of the
culture at 3000 g for 30 min, bacteria were harvested and
subsequently washed twice using sterile phosphate-buf-
fered saline (PBS), and diluted with medium to a concen-
tration of 1 9 106 spirochetes per ml. Aliquots were kept
at 20°. b-Glucan (b-1,3-(D)-glucan) was kindly pro-
vided by Professor David Williams (East Tennessee State
University, Johnson City, TN), and bacillus Calmette–
Guerin (BCG) vaccine was purchased from InterVax
(Markham, ON, Canada). Interferon-c (IFN-c) was pur-
chased from R&D Systems, and bovine serum albumin
(BSA) was purchased from Sigma-Aldrich.
Blood samples
Peripgheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats of healthy blood donors (Sanquin,
Nijmegen, the Netherlands). Venous blood of healthy vol-
unteers was drawn and genotyped after informed consent
(Radboudumc, Nijmegen, the Netherlands). TLR10 mRNA
expression by RNA sequencing was measured in 30 healthy
Dutch men who were randomly assigned to receive either
BCG (SSI, Copenhagen, Denmark) or placebo (the diluent
used to dissolve BCG) in a double-blind fashion.22 Blood
was drawn before vaccination and 1 month later (see Sup-
plementary material, Fig. S1a). Isolated monocytes at these
time-points were lysed in TRIzol reagent and stored at
80°. The study was approved by the Arnhem-Nijmegen
Medical Ethical Committee, NL50160.092.24.
TLR10 stimulation, cell surface expression in mono-
cytes, and quantitative trait locus (QTL) mapping were
studied in a cohort of healthy volunteers vaccinated with
BCG (300BCG cohort). In this cohort, 321 healthy Dutch
individuals (after exclusion of individuals who did not
meet the inclusion criteria, see below) of Western Euro-
pean descent (139 men and 182 women, age range 18–
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71 years) were included and vaccinated with BCG (Inter-
Vax). Before vaccination, and 2 weeks and 3 months after
vaccination, blood was drawn, and PBMCs were isolated
(Fig. 1b). The effect of TLR10 SNP N241H on trained
immunity in vitro was studied in the same cohort. This
in vitro assay was performed with isolated PBMCs
as described below. The 300BCG study was approved
by the Arnhem-Nijmegen Medical Ethical Committee,
NL58553.091.16. Volunteers were BCG naive and had not
lived in an area where tuberculosis was endemic. Inclu-
sion of volunteers and experiments was conducted
according to the principles expressed in the Declaration
of Helsinki. All volunteers gave written informed consent
before any material was taken.
PBMC isolation and stimulation
Cells were isolated by density centrifugation on Ficoll-
Paque (GE Healthcare, Chalfont St Giles, UK), washed
three times in PBS and resuspended in culture medium.
After isolation, 500 000 PBMCs were added to a round-
bottom 96-well plate (Greiner, Kremsm€unster, Austria).
Anti-TLR10 (10 lg/ml) or IgG1 isotype control (10 lg/
ml) was pre-incubated for 1 hr and subsequently
Pam3Cys (10 lg/ml) or B. burgdorferi spirochetes
(1 9 106/ml) were added for 24 hr at 37° and 5% CO2.
For cross-linking of TLR10, anti-TLR10 or IgG1 isotype
control (10 lg/ml) was coated to a flat-bottom 96-well
plate (Corning, Corning, NY) for 2 hr, washed with PBS,
and blocked for 1 hr with 1% BSA in PBS. After washing
twice with PBS, 500 000 PBMCs were added in each well
and subsequently incubated for 24 hr at 37° in 5% CO2.
Monocyte isolation and stimulation
Percoll monocytes were isolated by layering hyper-os-
motic Percoll solution [485% Percoll (Sigma-Aldrich),
415% sterile H2O, 016 M filter-sterilized NaCl] on
PBMCs. After 15 min centrifugation at 580 g, the inter-
phase layer was isolated, cells were washed with PBS, and
resuspended in culture medium. Percoll monocytes were
added to a polypropylene tube (1 million per tube) and
the stimuli or RPMI-1640 control were added. Cells were
cultured for 24 hr at 37° in RPMI-1640 supplemented
with 10% human pooled serum. To stimulate the cells, b-
glucan (5 lg/ml), BCG (10 lg/ml), Pam3Cys (10 lg/ml)
or IFN-c (20 ng/ml) was used. After 24 hr, cells were
used for flow cytometry experiments.
In vitro trained immunity assay
To increase the purity of Percoll-isolated monocytes, the
monocytes were adhered to polystyrene flat-bottom plates
(Corning) for 1 hr at 37° followed by washing with warm
PBS. Next, cells were pre-incubated with culture medium
supplemented with 10% human pooled serum as control,
or together with IgG1 isotype control or anti-TLR10 anti-
body (10 lg/ml) for 1 hr. Subsequently, culture medium
supplemented with 10% human pooled serum was added
as a control, or together with either 2 lg/ml b-glucan, or
5 lg/ml BCG. After 24 hr, cells were washed with warm
PBS and culture medium was added. Culture medium
was refreshed after 3 days of incubation. On day 6, cells
were re-stimulated with RPMI-1640, lipopolysaccharide
(LPS) (10 ng/ml), or Pam3Cys (10 lg/ml). After 24 hr,
supernatants were collected and stored at 20° until fur-
ther use (see Supplementary material, Fig. S1c). In the
in vitro system used, monocytes differentiated into
macrophages. However, the monocytes previously trained
with b-glucan or BCG undergo a different functional pro-
gram characterized by increased responsiveness even long
after the stimulus has been removed. This effect has been
termed trained immunity.
Cytokine measurements
Cytokine production was measured in supernatants using
commercial sandwich ELISA kits for human IL-6, tumor
necrosis factor-a (TNF-a), IL-1b and IL-1Ra (R&D Sys-
tems), in accordance with the manufacturer’s instructions.
Flow cytometry
Cells were washed with PBS supplemented with 1% BSA
and thereafter labeled with fluorochrome-conjugated mAbs.
After 30 min incubation at 4°, cells were washed, and sub-
sequently incubated for 45 min at 4° with Fix’n’Perm
(Thermo Fisher Scientific, Waltham, MA) and washed with
Perm Buffer (109 diluted Perm Buffer; BD Biosciences, San
Jose, CA). Next, cells for extracellular cell staining were
measured using a flow cytometer (CytoFLEX; Beckman
Coulter, Brea, CA). For intracellular staining, cells were
then labeled with mAbs for intracellular staining for 15 min
at room temperature. After washing with Perm Buffer
(Thermo Fisher Scientific), these cells were measured.
TLR10 expression was measured in a small subset of volun-
teers of the 300BCG cohort by adding antibodies to whole
blood, followed by incubation for 10 min at room tempera-
ture and subsequent addition of lysis buffer (Thermo Fisher
Scientific). Cells were incubated for 10 min, then measured
on the CytoFLEX. The following mAbs were used: mouse
anti-human CD45-allophycocyanin, CD45-knockout,
CD14-phycoerythrin-Cy5 (Beckman Coulter) and TLR10-
phycoerythrin (Thermo Fisher Scientific).
RNA sequencing
Monocytes were treated as described above, with either
RPMI-1640 as a control, LPS 10 ng/ml or 5 lg/ml
b-glucan. Monocytes (15 9 106) were seeded in six-well
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plates. At baseline, after 1 hr, 4 hr, 24 hr, 3 days, 6 days
and 24 hr after LPS re-stimulation cells were lysed in TRI-
zol and stored at 80° until further analysis as described
earlier.23 For BCG-vaccinated volunteers, monocytes were
isolated before and 1 month after BCG vaccination from
peripheral blood. From both experiments, total RNA was
extracted from cells using the Qiagen RNeasy RNA extrac-
tion kit, using on-column DNaseI treatment. Ribosomal
RNA was removed using the Ribo-Zero rRNA removal
kit. RNA was then fragmented into 200-bp fragments by
incubation for 4 min at 95° in fragmentation buffer
(200 mM Tris–acetate, 500 mM potassium acetate, 150 mM
magnesium acetate, pH 82). First-strand cDNA synthesis
was performed using SuperScript III, followed by synthesis
of the second cDNA strand. Library preparation was per-
formed using the KAPA HyperPrep kit, using the USER
enzyme to degrade the second cDNA strand. Quality of
cDNA and the efficiency of ribosomal RNA removal were
confirmed using quantitative RT-PCR using the IQ SYBR
Supermix, with primers for GAPDH, 18S and 28S rRNA.
TLR10 expression values (RPKM) were extracted from
RNA-sequencing data. Raw data files have been deposited
in the NCBI Gene Expression Omnibus under accession
numbers GEO: GSE104149 respectively GSE85243.
Genetic analysis
To investigate whether genetic variation influences trained
immunity responses, cytokine QTL mapping was conducted
using the genotypes and ex vivo cytokine measurements
upon Staphylococcus aureus stimulation before, and 2 weeks
and 3 months after vaccination of healthy individuals of
Western European ancestry from the 300BCG cohort
(NL58553.091.16). DNA samples of 325 individuals were
genotyped using the commercially available SNP chip, Infi-
nium Global Screening Array MD v1.0 from Illumina (San
Diego, CA). Genotype information on approximately 4 mil-
lion SNPs was obtained upon imputation (MAF > 5% and
R2 > 03 for imputation quality). Both genotype and cyto-
kine data on innate memory responses were obtained for a
total of 296 individuals. Genetic outliers, three samples due
to medication use (of which one was identified as a genetic
outlier), one sample due to onset of type 1 diabetes during
the study, and 18 evening vaccinated individuals were
excluded before QTL mapping. First, raw cytokine levels
were log-transformed and ratios of cytokine production
between the visits were taken as the change of cytokine levels.
The cytokine changes were mapped to genotype data using a
linear regression model with age and sex as covariates.
Statistics
Data were analyzed using a Wilcoxon signed-rank test or
a Mann–Whitney U-test using GRAPHPAD PRISM software
(version 5.03; GraphPad, San Diego, CA). Data are
expressed as mean  SEM of three or more independent
experiments, and values of P < 005 were considered sta-
tistically significant.
Results
TLR10 expression on the cell surface of monocytes
increases upon stimulation
Monocytes are important immune cells, and they have
been shown to express TLR10.4,7 We investigated TLR10
expression in monocytes stimulated for 24 hr with differ-
ent stimuli. Total TLR10 expression gated on
CD45+ CD14+ cells (Fig. 1a) was significantly increased
when stimulated with b-glucan or Pam3Cys, but not
BCG or IFN-c (Fig. 1b). Total TLR10 expression in
monocytes was higher than membrane-associated TLR10
expression (see Supplementary material, Fig. S2), indicat-
ing the presence of TLR10 in the cell. In addition, as seen
in Fig. 1(c), upon TLR10 stimulation with b-glucan or
Pam3Cys, the presence of TLR10 on the cell surface was
mainly affected, and not intracellular TLR10 expression.
Furthermore, the inhibitory function of TLR10 on the
innate immune system was validated. PBMCs were stimu-
lated with TLR2 ligands Pam3Cys or B. burgdorferi, which
support heterodimer formation and subsequent activation
of TLR10. An anti-TLR10 antibody was used to block the
receptor: this resulted in increased pro-inflammatory
cytokine production (see Supplementary material,
Fig. S3a), supporting the concept that TLR10 is an anti-
inflammatory receptor. On the other hand, TLR10 was
stimulated by coating anti-TLR10 antibodies on the well
(receptor cross-linking) and subsequently adding PBMCs,
which results in production of anti-inflammatory cyto-
kine IL-1Ra (see Supplementary material, Fig. S3b).
TLR10 expression during induction of trained
immunity
To identify if TLR10 is involved in the induction of
trained immunity, we first examined TLR10 expression in
monocytes using an in vitro trained immunity model.24
We induced trained immunity in vitro by incubating
monocytes with b-glucan for 24 hr and re-stimulation at
day 6 with LPS, as a non-specific stimulus. TLR10 mRNA
expression was not affected during the induction of
trained immunity (Fig. 2a). Thereafter, TLR10 protein
expression was determined by flow cytometry upon b-
glucan- and BCG-induced trained immunity in mono-
cytes in vitro. On average, membrane-associated TLR10
expression on day 7 was fourfold higher compared with
day 1 (see Supplementary material, Fig. S4), demonstrat-
ing up-regulation of TLR10 protein on the cell surface
during differentiation of monocytes to monocyte-derived
macrophages. As seen in Fig. 2(b), TLR10 expression is
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not affected upon LPS re-stimulation in b-glucan- and
BCG-stimulated cells in vitro, whereas TLR10 expression
in unstimulated cells was altered. Overall, these results
show that TLR10 mRNA, as well as TLR10 protein
expression, is not affected during b-glucan- and BCG-in-
duced trained immunity in vitro.
TLR10 affects trained immunity response in
monocytes
To assess whether TLR10 itself is able to modulate trained
immunity, trained immunity was induced in monocytes
in vitro by b-glucan or BCG in the presence or absence of
an anti-TLR10 antibody. As seen in Fig. 3(a), addition of
anti-TLR10 antibody did not significantly alter IL-6,
TNF-a and IL-1Ra cytokine production upon Pam3Cys
re-stimulation in b-glucan- and BCG-trained conditions.
To further investigate whether TLR10 may influence
trained immunity, we investigated the effect of TLR10
SNP N241H (rs11096957) on trained immunity. This
missense mutation is associated with several diseases with
an inflammatory pathophysiology,14,16,25 and individuals
homozygous for this SNP show increased pro-inflamma-
tory cytokine production.7 As seen in Fig. 3(b), individu-
als who are heterozygous or homozygous for this SNP
show decreased IL-6 and/or TNF-a production upon sec-
ondary stimulation after b-glucan-, or BCG-induced
trained immunity in vitro, suggesting that TLR10 posi-
tively affects trained immunity.
TLR10 expression in BCG-vaccinated healthy
individuals
As BCG vaccination is known to induce trained immunity
in vivo,19 TLR10 mRNA expression was assessed before
and 1 month after BCG vaccination. As seen in Fig. 4(a),
BCG vaccination did not affect TLR10 mRNA expression.
However, 2 weeks after BCG vaccination, increased TLR10
cell surface expression was observed (Fig. 4b). Moreover,
upon engagement of TLR10, more IL-1Ra was produced
2 weeks after BCG vaccination compared with before
BCG vaccination (Fig. 4c), suggesting that TLR10 plays a
role in BCG-induced trained immunity in vivo. To vali-
date the findings of in vitro BCG-induced trained immu-
nity, the effect of TLR10 genetic polymorphisms on
cytokine production upon BCG-induced trained immu-
nity was assessed in the 300BCG cohort from the Human
Functional Genomics Study. In this study, cis cytokine-
QTL mapping was performed in 296 healthy individuals
of ex vivo cytokine production upon S. aureus stimulation
before versus after BCG vaccination, representing a trained
immunity response. No significant cis cytokine-QTL was
observed for the TLR10 gene, indicating that TLR10 is not
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Figure 1. Toll-like receptor 10 (TLR10) expression on the cell surface of monocytes increases upon stimulation. (a) Flow cytometric gating strat-
egy. (b) Representative histogram, and (c) geometric mean fluorescence intensity of TLR10 expression upon stimulation of Percoll-isolated
monocytes with culture medium (control), b-glucan (5 lg/ml), bacillus Calmette–Guerin (BCG) (10 lg/ml), Pam3Cys (10 lg/ml) or interferon-c
(IFN-c) (20 ng/ml) for 24 hr (mean  SEM, n = 8–9, **P < 001, ***P < 00001, Wilcoxon signed-rank test).
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Discussion
Toll-like receptor 10 is the only anti-inflammatory mem-
ber of the TLR family. This anti-inflammatory role is
confirmed in the present study, in which blockade of the
TLR10 receptor up-regulated pro-inflammatory cytokine
production of PBMCs that were stimulated with TLR
ligands. Furthermore, we expanded the understanding of
the role of TLR10 in regulating innate immunity, by
studying the role of TLR10 in trained immunity in vitro
and in vivo. While a TLR10 missense SNP affected BCG-
and b-glucan-induced trained immunity in vitro, no
TLR10 genetic variant significantly affected the induction
of trained immunity by BCG vaccination in healthy indi-
viduals.
Recently, it has been shown that TLR10 is mainly
expressed in the endosomes of a human monocytic cell
line. It has been suggested that intracellular TLR10 recog-
nizes double-stranded RNA and thereby suppresses IFN
type I production.26 Here we show that TLR10 is
expressed both extracellularly and intracellularly in
human CD45+ CD14+ monocytes. Additionally, upon
stimulation, extracellular TLR10 expression increases
whereas intracellular TLR10 expression is not affected.
This suggests that TLR10 exerts its main biological func-
tion on the cell surface of monocytes, most likely as an
anti-inflammatory receptor competing with ligands for
other TLRs. Upon stimulation of PBMCs in the presence
of a blocking anti-TLR10 antibody, increased production
of pro-inflammatory cytokines IL-6, TNF-a and IL-1b
was observed. In addition, we report an increased pro-
duction of IL-1Ra, the inhibitor of IL-1 signaling, upon
engagement and cross-linking of TLR10. These anti-in-
flammatory properties of TLR10 were also observed in
earlier studies,4,7,10,11 confirming that TLR10 functions as
an anti-inflammatory receptor.
The importance of trained immunity in autoimmune
and inflammatory diseases is becoming increasingly
clear.27 It is therefore essential to identify the modulatory
mechanisms that control the inappropriate induction of
trained immunity, and we hypothesized that TLR10 may
have such a regulatory role. TLR10 mRNA as well as
TLR10 protein expression is not altered during the induc-
tion of b-glucan- and BCG-induced trained immunity
in vitro. To investigate whether the induction of trained
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Figure 2. Toll-like receptor 10 (TLR10) expression during induction of trained immunity in monocytes. (a) Percoll-isolated monocytes were
stimulated for 24 hr with b-glucan (5 lg/ml) or lipopolysaccharide (LPS) (10 ng/ml), and re-stimulated for 24 hr with LPS after 6 days. Cells
were analyzed by performing RNA sequencing at baseline, after 1 hr, 4 hr, 1 day, 6 days and 24 hr after LPS restimulation. TLR10 mRNA
expression is shown as average reads per kilobase million (RPKM) (between n = 2 and n = 5 donors were sequenced per time-point. (b) Percoll-
isolated monocytes were stimulated for 24 hr with b-glucan (2 lg/ml) or bacillus Calmette–Guerin (BCG) (5 lg/ml) and re-stimulated for 24 hr
with LPS (10 ng/ml) after 6 days. (c) Representative histograms of TLR10 protein expression measured in CD45+ CD14+ cells using flow cytome-
try (Mean  SEM, n = 6, *P < 005, **P < 001, Wilcoxon signed-rank test).
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was added while inducing trained immunity in vitro. This
tended to reduce pro-inflammatory cytokine responses in
b-glucan- or BCG-induced trained immunity, but these
results were not statistically significant. To provide a last
argument towards a role, or the absence of it, for TLR10










































































Figure 3. Toll-like receptor 10 (TLR10) affects trained immunity response in monocyte. (a) Percoll-isolated monocytes were adhered for 1 hr in
a 96-well plate. Anti-TLR10 antibody and IgG1 isotype control were added for 1 hr. Subsequently b-glucan (2 lg/ml) or bacillus Calmette–
Guerin (BCG) (5 lg/ml) was added for 24 hr, and re-stimulated for 24 hr with Pam3Cys after 6 days. Cytokine levels were determined in the
supernatant by using ELISA (mean  SEM, n ≥ 6, n.s., Wilcoxon signed-rank test). (b) Percoll-isolated monocytes were stimulated for 24 hr
with b-glucan (2 lg/ml) or BCG (5 lg/ml) and re-stimulated for 24 hr with LPS (10 ng/ml) after 6 days. Cytokine levels were determined in the
supernatant by using ELISA (mean  SEM, *P < 005, **P < 001, ***P < 0001, Mann–Whitney U-test).
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Figure 4. Toll-like receptor 10 (TLR10) expression in bacillus Calmette–Guerin (BCG) -vaccinated healthy individuals. (a) TLR10 mRNA expres-
sion in monocytes was analyzed by performing RNA sequencing before and 1 month after BCG vaccination (n = 6). TLR10 mRNA expression is
shown as average reads per kilobase million (RPKM). (b) TLR10 cell surface expression on CD45+ CD14+ cells in whole blood was measured
using flow cytometry before and 2 weeks after BCG vaccination. Expressed in mean fluorescence intensity (MFI) (n = 10, *P > 005, Wilcoxon
signed-rank test). (c) Anti-TLR10 antibody (10 lg/ml) was added to the wells for 2 hr, blocked with phosphate-buffered saline + 1% bovine
serum albumin for 1 hr, and thereafter PBMCs were added and incubated for 24 hr. Cytokine levels were determined in the supernatant by using
ELISA (Mean  SEM, n ≥ 15 for t = 0 and t = 1, n = 6 for t = 2, ***P < 00001, Wilcoxon signed-rank test).
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TLR10 SNP N241H on b-glucan- and BCG-induced cyto-
kine production. This SNP is a missense mutation associ-
ated with a reduced risk of prostate cancer,16 complicated
skin and skin structure infections,14 and osteoarthritis.25
We previously showed that healthy individuals carrying
this SNP display increased pro-inflammatory cytokine
production upon direct TLR2 stimulation, suggesting a
reduction of the anti-inflammatory actions of TLR10.7
Surprisingly, in the current study, we demonstrate that
healthy individuals who are heterozygous or homozygous
carriers of this SNP show decreased cytokine production
upon b-glucan- and BCG-induced trained immunity
in vitro. This suggests that the effect of TLR10 on innate
immune responses differs depending on the timing and
setting of TLR stimulation: inhibiting pro-inflammatory
responses upon direct stimulation, while promoting
trained immunity.
Furthermore, to provide a definitive proof of the impor-
tance of TLR10 for the induction of trained immunity, we
assessed its effects on trained immunity induced in vivo in
a cohort of healthy individuals who received BCG vaccina-
tion. Confirming the in vitro experiments, the mRNA
expression of TLR10 was not affected upon BCG-induced
trained immunity in vivo. Yet, increased TLR10 expression
on the cell surface of monocytes was observed, as well as an
increased ability to produce IL-1Ra upon engagement of
TLR10 ex vivo. However, TLR10 polymorphisms were not
associated with the capacity of BCG vaccination to induce
heterologous cytokine responses, a hallmark of trained
immunity. This argues that while TLR10 expression is
affected upon BCG vaccination, it does not significantly
contribute to the process of trained immunity in vivo.
Importantly, these analyses were performed on a relatively
small cohort of 296 individuals, and larger cohorts may still
identify small effects. However, a major role of TLR10 for
the modulation of trained immunity is unlikely.
To conclude, we confirm anti-inflammatory properties
of TLR10 and observed increased expression of TLR10 on
the cell surface of monocytes upon direct stimulation.
Furthermore, TLR10 moderately affects the induction of
b-glucan- and BCG-induced trained immunity in vitro.
However, genetic variation in the TLR10 gene does not
regulate the induction of trained immunity by BCG vac-
cination in vivo, arguing against an essential role of
TLR10 in this process.
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